16.43 % to Target, UBS Reconfirms ‘”Buy”’ Rating on Bristol Myers (NYSE:BMY) Shares Today

December 7, 2017 - By Vivian Currie

 16.43 % to Target, UBS Reconfirms ‘

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It dropped, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Carl Domino Inc reported 17,170 shares. Riverpoint Mgmt Limited stated it has 18,848 shares or 0.07% of all its holdings. Patten Group Incorporated reported 5,533 shares. Ibm Retirement Fund stated it has 40,328 shares or 0.47% of all its holdings. 13,380 are owned by Roundview Limited Liability. Chem National Bank & Trust holds 58,198 shares or 0.35% of its portfolio. Harvest Mgmt Limited Com owns 12,500 shares. Palisades Hudson Asset Mgmt Lp, Florida-based fund reported 5,324 shares. Burke Herbert Bank & Trust Tru Com accumulated 14,732 shares. Wealth Planning Ltd holds 6,968 shares. holds 0.01% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 160,401 shares. Synovus Fin Corporation stated it has 166,260 shares. Bowen Hanes And holds 0.03% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 10,805 shares. 357,595 are held by Altrinsic Glob Advsrs Lc. 121,610 were reported by Cornerstone Capital.

Bristol Myers (NYSE:BMY) Rating Reaffirmed

New York: In analysts report published on Friday morning, UBS reconfirmed their “Buy” rating on Bristol Myers (NYSE:BMY) shares. They now have a $72.0 price target on the company. UBS’s target suggests a potential upside of 16.43 % from the company’s current stock price.

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It dropped, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Carl Domino Inc reported 17,170 shares. Riverpoint Mgmt Limited stated it has 18,848 shares or 0.07% of all its holdings. Patten Group Incorporated reported 5,533 shares. Ibm Retirement Fund stated it has 40,328 shares or 0.47% of all its holdings. 13,380 are owned by Roundview Limited Liability. Chem National Bank & Trust holds 58,198 shares or 0.35% of its portfolio. Harvest Mgmt Limited Com owns 12,500 shares. Palisades Hudson Asset Mgmt Lp, Florida-based fund reported 5,324 shares. Burke Herbert Bank & Trust Tru Com accumulated 14,732 shares. Wealth Planning Ltd holds 6,968 shares. holds 0.01% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 160,401 shares. Synovus Fin Corporation stated it has 166,260 shares. Bowen Hanes And holds 0.03% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 10,805 shares. 357,595 are held by Altrinsic Glob Advsrs Lc. 121,610 were reported by Cornerstone Capital.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 1.12% above currents $61.84 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $68.0 target in Thursday, November 16 report. The firm has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. Cowen & Co maintained it with “Hold” rating and $65.0 target in Thursday, October 19 report. The rating was maintained by Deutsche Bank with “Hold” on Monday, July 17. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Monday, November 13. BMO Capital Markets has “Sell” rating and $49.0 target. Piper Jaffray maintained the stock with “Hold” rating in Thursday, October 26 report. As per Thursday, July 27, the company rating was maintained by Leerink Swann. As per Wednesday, December 2, the company rating was upgraded by Guggenheim. The company was initiated on Friday, December 18 by Atlantic Securities. As per Wednesday, October 25, the company rating was maintained by Citigroup.

The stock increased 1.43% or $0.87 during the last trading session, reaching $61.84. About 5.12 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 7, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35 % or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10 billion for 23.07 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67 % negative EPS growth.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $101.21 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.26 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Bloomberg.com which released: “Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact” on December 01, 2017, also Investorplace.com with their article: “Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating” published on November 24, 2017, Investorplace.com published: “Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating” on December 01, 2017. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Nasdaq.com and their article: “Madrona Financial Services, LLC Buys ONEOK Inc, Boeing Co, Bristol-Myers …” published on November 09, 2017 as well as Investorplace.com‘s news article titled: “3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers …” with publication date: December 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.